Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: A case series from the Johns Hopkins Itch Clinic was written by Khanna, Raveena;Kwon, Christina D.;Patel, Sagar P.;Belzberg, Micah;Williams, Kyle A.;Khanna, Ramona;Boozalis, Emily;Kwatra, Shawn G.. And the article was included in Journal of the American Academy of Dermatology in 2020.COA of Formula: C32H39NO4 The following contents are mentioned in the article:
Chronic itch that is refractory to conventional therapy is a debilitating symptom that can be difficult to manage clin. With limited United States Food and Drug Administration approved therapies specifically targeting itch, there is a clin. need for rapid-acting agents that can disrupt the itch-scratch cycle for patients with refractory chronic pruritus. Although the mechanism of pruritus is poorly understood, recent breakthroughs highlight a key role for the opioid axis where 渭-opioid 魏 opioid agonist as a salvage therapy providing rapid relief for chronic itch that is refractory to standard first-line therapies. Most reports to date however describe the effectiveness of butorphanol administration for morphine-induced pruritus, because analgesic opioid agents often produce itch as an adverse effect. As such, few studies have described the clin. implementation of intranasal butorphanol in treating intractable pruritus associated with a variety of etiologies. We investigated the efficacy of intranasal butorphanol as a rescue therapy for chronic, refractory pruritus. We report a series of 16 patients who were treated with a butorphanol, 10 mg/mL inhaler as needed, up to every 4 h for intractable pruritus from June 2017 to July 2019 at the Johns Hopkins Itch Clinic. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0COA of Formula: C32H39NO4).
2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine has a role as a reagent, a protic solvent, a base, a catalyst, a plant metabolite, a human metabolite and a non-polar solvent. Industrially, piperidine is produced by the hydrogenation of pyridine, usually over a molybdenum disulfide catalyst. Pyridine can also be reduced to piperidine via a modified Birch reduction using sodium in ethanol.COA of Formula: C32H39NO4
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem